Nutraceuticals in Parkinson’s Disease

NeuroMolecular Medicine

Volumn 18, Issue 3, 2016, Pages 306-321

  Hang, Liting ^a,b,c   Basil, Adeline Henry ^a   Lim, Kah Leong ^a,c,d  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

AMPK; Mitochondria; Neurodegeneration; Parkin; Parkinson s disease

Indexed keywords

ADENYLATE KINASE; EPIGALLOCATECHIN GALLATE; GENISTEIN; GINSENOSIDE; NUTRACEUTICAL; SULFONYLUREA; CATECHIN; NEUROPROTECTIVE AGENT;

ANTIOXIDANT ACTIVITY; DRUG SAFETY; ENZYME ACTIVATION; HOMEOSTASIS; HUMAN; INFLAMMATION; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; DIETARY SUPPLEMENT; METABOLISM;

CATECHIN; DIETARY SUPPLEMENTS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 84965010994     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-016-8398-6     Document Type: Review

References (134)

1. Ahmad, M., Saleem, S., Ahmad, A. S., Yousuf, S., Ansari, M. A., Khan, M. B., et al. (2005). Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: Neurobehavioural, neurochemical and immunohistochemical evidences. Journal of Neurochemistry, 93(1), 94–104. doi:10.1111/j.1471-4159.2005.03000.x.
2. Albani, D., Polito, L., Batelli, S., De Mauro, S., Fracasso, C., Martelli, G., et al. (2009). The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1–42) peptide. Journal of Neurochemistry, 110(5), 1445–1456. doi:10.1111/j.1471-4159.2009.06228.x.
3. Ali, S., Shultz, J. L., & Ikram Ul, H. (2007). High performance microbiological transformation of l-tyrosine to l-dopa by Yarrowia lipolytica NRRL-143. BMC Biotechnology, 7, 50. doi:10.1186/1472-6750-7-50.
4. Anderson, D. W., Bradbury, K. A., & Schneider, J. S. (2008). Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. European Journal of Neuroscience, 28(3), 610–617. doi:10.1111/j.1460-9568.2008.06356.x.
5. Baluchnejadmojarad, T., Roghani, M., Nadoushan, M. R., & Bagheri, M. (2009). Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phytotherapy Research, 23(1), 132–135. doi:10.1002/ptr.2564.
6. Beal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998). Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Research, 783(1), 109–114.
7. Bender, A., Koch, W., Elstner, M., Schombacher, Y., Bender, J., Moeschl, M., et al. (2006). Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial. Neurology, 67(7), 1262–1264. doi:10.1212/01.wnl.0000238518.34389.12.
8. Bournival, J., Quessy, P., & Martinoli, M. G. (2009). Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cellular and Molecular Neurobiology, 29(8), 1169–1180. doi:10.1007/s10571-009-9411-5.
9. Bousquet, M., Saint-Pierre, M., Julien, C., Salem, N, Jr, Cicchetti, F., & Calon, F. (2008). Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson’s disease. The FASEB Journal, 22(4), 1213–1225. doi:10.1096/fj.07-9677com.
10. Bureau, G., Longpre, F., & Martinoli, M. G. (2008). Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. Journal of Neuroscience Research, 86(2), 403–410. doi:10.1002/jnr.21503.
11. Carroll, R. G., Hollville, E., & Martin, S. J. (2014). Parkin sensitizes toward apoptosis induced by mitochondrial depolarization through promoting degradation of Mcl-1. [Research Support, Non-U.S. Gov’t]. Cell Reports, 9(4), 1538–1553. doi:10.1016/j.celrep.2014.10.046.
12. Chao, J., Yu, M. S., Ho, Y. S., Wang, M., & Chang, R. C. (2008). Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radical Biology and Medicine, 45(7), 1019–1026. doi:10.1016/j.freeradbiomed.2008.07.002.
13. Chao, J., Leung, Y., Wang, M., & Chang, R. C. (2012). Nutraceuticals and their preventive or potential therapeutic value in Parkinson’s disease. Nutrition Reviews, 70(7), 373–386. doi:10.1111/j.1753-4887.2012.00484.x.
14. Cheah, I. K., & Halliwell, B. (2012). Ergothioneine; antioxidant potential, physiological function and role in disease. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1822(5), 784–793. doi:10.1016/j.bbadis.2011.09.017.
15. Chen, H., Zhang, S. M., Hernán, M. A., Willett, W. C., & Ascherio, A. (2003). Dietary intakes of fat and risk of Parkinson’s disease. American Journal of Epidemiology, 157(11), 1007–1014. doi:10.1093/aje/kwg073.
16. Chen, X. C., Zhou, Y. C., Chen, Y., Zhu, Y. G., Fang, F., & Chen, L. M. (2005). Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacologica Sinica, 26(1), 56–62. doi:10.1111/j.1745-7254.2005.00019.x.
17. Chen, J., Tang, X. Q., Zhi, J. L., Cui, Y., Yu, H. M., Tang, E. H., et al. (2006). Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis, 11(6), 943–953. doi:10.1007/s10495-006-6715-5.
18. Chen, S. F., Hsu, C. W., Huang, W. H., & Wang, J. Y. (2008). Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury. British Journal of Pharmacology, 155(8), 1279–1296. doi:10.1038/bjp.2008.345.
19. Cheng, Y., He, G., Mu, X., Zhang, T., Li, X., Hu, J., et al. (2008). Neuroprotective effect of baicalein against MPTP neurotoxicity: Behavioral, biochemical and immunohistochemical profile. Neuroscience Letters, 441(1), 16–20. doi:10.1016/j.neulet.2008.05.116.
20. Choi, J. S., Park, C., & Jeong, J. W. (2010). AMP-activated protein kinase is activated in Parkinson’s disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochemical and Biophysical Research Communications, 391(1), 147–151. doi:10.1016/j.bbrc.2009.11.022.
21. Cleren, C., Yang, L., Lorenzo, B., Calingasan, N. Y., Schomer, A., Sireci, A., et al. (2008). Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. Journal of Neurochemistry, 104(6), 1613–1621. doi:10.1111/j.1471-4159.2007.05097.x.
22. Dasgupta, B., & Milbrandt, J. (2007). Resveratrol stimulates AMP kinase activity in neurons. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Proceedings of the National Academy of Sciences of the United States of America, 104(17), 7217–7222. doi:10.1073/pnas.0610068104.
23. de Lau, L. M., Bornebroek, M., Witteman, J. C., Hofman, A., Koudstaal, P. J., & Breteler, M. M. (2005). Dietary fatty acids and the risk of Parkinson disease: The Rotterdam study. Neurology, 64(12), 2040–2045. doi:10.1212/01.wnl.0000166038.67153.9f.
24. Denny Joseph, K. M., & Muralidhara, (2015). Combined oral supplementation of fish oil and quercetin enhances neuroprotection in a chronic rotenone rat model: Relevance to Parkinson’s disease. Neurochemical Research, 40(5), 894–905. doi:10.1007/s11064-015-1542-0.
25. Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., et al. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68(5), 384–386. doi:10.1212/01.wnl.0000247740.47667.03.
26. Etminan, M., Gill, S. S., & Samii, A. (2005). Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: A meta-analysis. Lancet Neurology, 4(6), 362–365. doi:10.1016/s1474-4422(05)70097-1.
27. Evatt, M. L., Delong, M. R., Khazai, N., Rosen, A., Triche, S., & Tangpricha, V. (2008). Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Archives of Neurology, 65(10), 1348–1352. doi:10.1001/archneur.65.10.1348.
28. Fahn, S. (1991). An open trial of high-dosage antioxidants in early Parkinson’s disease. American Journal of Clinical Nutrition, 53(1 Suppl), 380s–382s.
29. Fang, S. C., Hsu, C. L., & Yen, G. C. (2008). Anti-inflammatory effects of phenolic compounds isolated from the fruits of Artocarpus heterophyllus. Journal of Agriculture and Food Chemistry, 56(12), 4463–4468. doi:10.1021/jf800444g.
30. Ferretta, A., Gaballo, A., Tanzarella, P., Piccoli, C., Capitanio, N., Nico, B., et al. (2014). Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson’s disease. [Research Support, Non-U.S. Gov’t]. Biochimica et Biophysica Acta, 1842(7), 902–915. doi:10.1016/j.bbadis.2014.02.010.
31. Garcia-Arencibia, M., Garcia, C., & Fernandez-Ruiz, J. (2009). Cannabinoids and Parkinson’s disease. CNS & Neurological Disorders: Drug Targets, 8(6), 432–439.
32. Garcion, E., Wion-Barbot, N., Montero-Menei, C. N., Berger, F., & Wion, D. (2002). New clues about vitamin D functions in the nervous system. Trends in Endocrinology and Metabolism, 13(3), 100–105.
33. Giridharan, V. V., Thandavarayan, R. A., & Konishi, T. (2011). Effect of Shengmai-san on cognitive performance and cerebral oxidative damage in BALB/c mice. Journal of Medicinal Food, 14(6), 601–609. doi:10.1089/jmf.2010.1362.
34. Goldman, S. M. (2014). Environmental toxins and Parkinson’s disease. Annual Review of Pharmacology and Toxicology, 54, 141–164. doi:10.1146/annurev-pharmtox-011613-135937.
35. Gongora-Alfaro, J. L. (2010). Caffeine as a preventive drug for Parkinson’s disease: Epidemiologic evidence and experimental support. Revista de Neurologia, 50(4), 221–229.
36. Green, D. R., & Kroemer, G. (2004). The pathophysiology of mitochondrial cell death. Science, 305(5684), 626–629. doi:10.1126/science.1099320305/5684/626.
37. Guo, S., Yan, J., Yang, T., Yang, X., Bezard, E., & Zhao, B. (2007). Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson’s disease through inhibition of ROS-NO pathway. Biological Psychiatry, 62(12), 1353–1362. doi:10.1016/j.biopsych.2007.04.020.
38. Haleagrahara, N., Siew, C. J., Mitra, N. K., & Kumari, M. (2011). Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxidative stress biomarkers in the rat striatum. Neuroscience Letters, 500(2), 139–143. doi:10.1016/j.neulet.2011.06.021.
39. Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P., & Hattori, N. (2015). Identification of novel biomarkers for Parkinson’s disease by metabolomic technologies. Journal of Neurology, Neurosurgery and Psychiatry,. doi:10.1136/jnnp-2014-309676.
40. HP-200 in Parkinson’s Disease Study Group. (1995). An alternative medicine treatment for Parkinson’s disease: Results of a multicenter clinical trial. Journal of Alternative and Complementary Medicine, 1(3), 249–255.
41. Hussian, G., & Manyam, B. V. (1997). Mucuna pruriens proves more effective than l-DOPA in Parkinson’s disease animal model. Phytotherapy Research, 11(6), 419–423. doi:10.1002/(SICI)1099-1573(199709)11:6<419:AID-PTR120>3.0.CO;2-Q.
42. Hwang, J. T., Kwon, D. Y., & Yoon, S. H. (2009). AMP-activated protein kinase: A potential target for the diseases prevention by natural occurring polyphenols. New Biotechnology, 26(1–2), 17–22. doi:10.1016/j.nbt.2009.03.005.
43. Jagatha, B., Mythri, R. B., Vali, S., & Bharath, M. M. (2008). Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson’s disease explained via in silico studies. Free Radical Biology and Medicine, 44(5), 907–917. doi:10.1016/j.freeradbiomed.2007.11.011.
44. Jahromi, S. R., Haddadi, M., Shivanandappa, T., & Ramesh, S. R. (2015). Attenuation of neuromotor deficits by natural antioxidants of Decalepis hamiltonii in transgenic Drosophila model of Parkinson’s disease. Neuroscience, 293, 136–150. doi:10.1016/j.neuroscience.2015.02.048.
45. Jenner, P. (1998). Oxidative mechanisms in nigral cell death in Parkinson’s disease. Movement Disorders, 13(Suppl 1), 24–34.
46. Jiang, M., Porat-Shliom, Y., Pei, Z., Cheng, Y., Xiang, L., Sommers, K., et al. (2010). Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. Journal of Neurochemistry, 114(2), 419–429. doi:10.1111/j.1471-4159.2010.06752.x.
47. Johnson, S. (2001). Micronutrient accumulation and depletion in schizophrenia, epilepsy, autism and Parkinson’s disease? Medical Hypotheses, 56(5), 641–645. doi:10.1054/mehy.2000.1302.
48. Kang, X., Chen, J., Xu, Z., Li, H., & Wang, B. (2007). Protective effects of Ginkgo biloba extract on paraquat-induced apoptosis of PC12 cells. Toxicology in Vitro, 21(6), 1003–1009. doi:10.1016/j.tiv.2007.02.004.
49. Katzenschlager, R., Evans, A., Manson, A., Patsalos, P. N., Ratnaraj, N., Watt, H., et al. (2004). Mucuna pruriens in Parkinson’s disease: A double blind clinical and pharmacological study. Journal of Neurology, Neurosurgery and Psychiatry, 75(12), 1672–1677. doi:10.1136/jnnp.2003.028761.
50. Kaul, S., Anantharam, V., Yang, Y., Choi, C. J., Kanthasamy, A., & Kanthasamy, A. G. (2005). Tyrosine phosphorylation regulates the proteolytic activation of protein kinase Cδ in dopaminergic neuronal cells. Journal of Biological Chemistry, 280(31), 28721–28730. doi:10.1074/jbc.M501092200.
51. Khan, M. M., Ahmad, A., Ishrat, T., Khan, M. B., Hoda, M. N., Khuwaja, G., et al. (2010). Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson’s disease. Brain Research, 1328, 139–151. doi:10.1016/j.brainres.2010.02.031.
52. Kim, M. S., Lee, J. I., Lee, W. Y., & Kim, S. E. (2004). Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson’s disease. Phytotherapy Research, 18(8), 663–666. doi:10.1002/ptr.1486.
53. Kim, T. W., Cho, H. M., Choi, S. Y., Suguira, Y., Hayasaka, T., Setou, M., et al. (2013). (ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson’s disease. Cell Death and Disease, 4, e919. doi:10.1038/cddis.2013.447cddis2013447.
54. Kim, H. S., Quon, M. J., & Kim, J. A. (2014). New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol, 2, 187–195. doi:10.1016/j.redox.2013.12.022.
55. Kirik, D., Georgievska, B., Rosenblad, C., & Bjorklund, A. (2001). Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson’s disease. European Journal of Neuroscience, 13(8), 1589–1599.
56. Kiriyama, K., Ohtaki, H., Kobayashi, N., Murai, N., Matsumoto, M., Sasaki, S., et al. (2015). A nucleoprotein-enriched diet suppresses dopaminergic neuronal cell loss and motor deficit in mice with MPTP-induced Parkinson’s disease. Journal of Molecular Neuroscience, 55(3), 803–811. doi:10.1007/s12031-014-0432-2.
57. Knekt, P., Kilkkinen, A., Rissanen, H., Marniemi, J., Saaksjarvi, K., & Heliovaara, M. (2010). Serum vitamin D and the risk of Parkinson disease. Archives of Neurology, 67(7), 808–811. doi:10.1001/archneurol.2010.120.
58. Krishnaveni, R., Rathod, V., Thakur, M. S., & Neelgund, Y. F. (2009). Transformation of l-tyrosine to l-dopa by a novel fungus, Acremonium rutilum, under submerged fermentation. Current Microbiology, 58(2), 122–128. doi:10.1007/s00284-008-9287-5.
59. Lamberti, P., Zoccolella, S., Armenise, E., Lamberti, S. V., Fraddosio, A., de Mari, M., et al. (2005). Hyperhomocysteinemia in l-dopa treated Parkinson’s disease patients: Effect of cobalamin and folate administration. European Journal of Neurology, 12(5), 365–368. doi:10.1111/j.1468-1331.2004.00973.x.
60. Lee, M. K., Kang, S. J., Poncz, M., Song, K. J., & Park, K. S. (2007). Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Experimental & Molecular Medicine, 39(3), 376–384. doi:10.1038/emm.2007.42.
61. Lee, C. W., Wong, L. L., Tse, E. Y., Liu, H. F., Leong, V. Y., Lee, J. M., et al. (2012). AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. [Research Support, Non-U.S. Gov’t]. Cancer Research, 72(17), 4394–4404. doi:10.1158/0008-5472.CAN-12-0429.
62. Leppa, S., & Bohmann, D. (1999). Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene, 18(45), 6158–6162. doi:10.1038/sj.onc.1203173.
63. Levites, Y., Weinreb, O., Maor, G., Youdim, M. B., & Mandel, S. (2001). Green tea polyphenol (−)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. Journal of Neurochemistry, 78(5), 1073–1082.
64. Li, C., Liu, V. W., Chiu, P. M., Chan, D. W., & Ngan, H. Y. (2012). Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications. [Research Support, Non-U.S. Gov’t]. BMC Cancer, 12, 357. doi:10.1186/1471-2407-12-357.
65. Lim, K. L., & Zhang, C. W. (2013). Molecular events underlying Parkinson’s disease—An interwoven tapestry. Frontiers in Neurology, 4, 33. doi:10.3389/fneur.2013.00033.
66. Lin, J. Y., Chung, S. Y., Lin, M. C., & Cheng, F. C. (2002). Effects of magnesium sulfate on energy metabolites and glutamate in the cortex during focal cerebral ischemia and reperfusion in the gerbil monitored by a dual-probe microdialysis technique. Life Sciences, 71(7), 803–811.
67. Liu, T. J., Yeh, Y. C., Ting, C. T., Lee, W. L., Wang, L. C., Lee, H. W., et al. (2008). Ginkgo biloba extract 761 reduces doxorubicin-induced apoptotic damage in rat hearts and neonatal cardiomyocytes. Cardiovascular Research, 80(2), 227–235. doi:10.1093/cvr/cvn192.
68. Liu, L.-F., Song, J.-X., Lu, J.-H., Huang, Y.-Y., Zeng, Y., Chen, L.-L., et al. (2015). Tianma Gouteng Yin, a Traditional Chinese Medicine decoction, exerts neuroprotective effects in animal and cellular models of Parkinson’s disease. Scientific Reports, 5, 16862. doi:10.1038/srep16862.
69. Lu, K. T., Ko, M. C., Chen, B. Y., Huang, J. C., Hsieh, C. W., Lee, M. C., et al. (2008). Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. Journal of Agriculture and Food Chemistry, 56(16), 6910–6913. doi:10.1021/jf8007212.
70. Mandel, S., Weinreb, O., Amit, T., & Youdim, M. B. (2004). Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (−)-epigallocatechin-3-gallate: Implications for neurodegenerative diseases. Journal of Neurochemistry, 88(6), 1555–1569.
71. Mandel, S., Weinreb, O., Reznichenko, L., Kalfon, L., & Amit, T. (2006). Green tea catechins as brain-permeable, non toxic iron chelators to “iron out iron” from the brain. Journal of Neural Transmission, 71(Suppl), 249–257.
72. Manyam, B. V., Dhanasekaran, M., & Hare, T. A. (2004). Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res, 18(9), 706–712. doi:10.1002/ptr.1514.
73. Martin, A., Youdim, K., Szprengiel, A., Shukitt-Hale, B., & Joseph, J. (2002). Roles of vitamins E and C on neurodegenerative diseases and cognitive performance. Nutrition Reviews, 60(10 Pt 1), 308–326.
74. Martin, I., Kim, J. W., Dawson, V. L., & Dawson, T. M. (2014). LRRK2 pathobiology in Parkinson’s disease. [Research Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov’tReview]. Journal of Neurochemistry, 131(5), 554–565. doi:10.1111/jnc.12949.
75. Matthews, R. T., Ferrante, R. J., Klivenyi, P., Yang, L., Klein, A. M., Mueller, G., et al. (1999). Creatine and cyclocreatine attenuate MPTP neurotoxicity. Experimental Neurology, 157(1), 142–149. doi:10.1006/exnr.1999.7049.
76. Miller, J. W., Selhub, J., Nadeau, M. R., Thomas, C. A., Feldman, R. G., & Wolf, P. A. (2003). Effect of l-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status. Neurology, 60(7), 1125–1129.
77. Mu, X., He, G., Cheng, Y., Li, X., Xu, B., & Du, G. (2009). Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacology, Biochemistry and Behavior, 92(4), 642–648. doi:10.1016/j.pbb.2009.03.008.
78. Mukherjee, S. K., Klaidman, L. K., Yasharel, R., & Adams, J. D, Jr. (1997). Increased brain NAD prevents neuronal apoptosis in vivo. European Journal of Pharmacology, 330(1), 27–34.
79. Muller, T., Buttner, T., Gholipour, A. F., & Kuhn, W. (2003). Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neuroscience Letters, 341(3), 201–204.
80. Nagashayana, N., Sankarankutty, P., Nampoothiri, M. R., Mohan, P. K., & Mohanakumar, K. P. (2000). Association of l-DOPA with recovery following Ayurveda medication in Parkinson’s disease. Journal of the Neurological Sciences, 176(2), 124–127.
81. Nevado, J., Sanz, R., Sanchez-Rodriguez, C., Garcia-Berrocal, J. R., Martin-Sanz, E., Gonzalez-Garcia, J. A., et al. (2010). Ginkgo biloba extract (EGb761) protects against aging-related caspase-mediated apoptosis in rat cochlea. Acta Oto-Laryngologica, 130(10), 1101–1112. doi:10.3109/00016481003713657.
82. Ng, C. H., Guan, M. S., Koh, C., Ouyang, X., Yu, F., Tan, E. K., et al. (2012a). AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson’s disease. Journal of Neuroscience, 32(41), 14311–14317. doi:10.1523/jneurosci.0499-12.2012.
83. Ng, T. L., Leprivier, G., Robertson, M. D., Chow, C., Martin, M. J., Laderoute, K. R., et al. (2012b). The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death and Differentiation, 19(3), 501–510. doi:10.1038/cdd.2011.119.
84. Olanow, C. W. (2003). Dietary vitamin E and Parkinson’s disease: Something to chew on. Lancet Neurology, 2(2), 74.
85. Parkinson Study Group (1993). Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. New England Journal of Medicine, 328(3), 176–183. doi:10.1056/nejm199301213280305.
86. Pallas, M., Verdaguer, E., Tajes, M., Gutierrez-Cuesta, J., & Camins, A. (2008). Modulation of sirtuins: New targets for antiageing. Recent Patents on CNS Drug Discovery, 3(1), 61–69.
87. Pallas, M., Casadesus, G., Smith, M. A., Coto-Montes, A., Pelegri, C., Vilaplana, J., et al. (2009). Resveratrol and neurodegenerative diseases: Activation of SIRT1 as the potential pathway towards neuroprotection. Current Neurovascular Research, 6(1), 70–81.
88. Pan, T., Jankovic, J., & Le, W. (2003). Potential therapeutic properties of green tea polyphenols in Parkinson’s disease. Drugs and Aging, 20(10), 711–721.
89. Pandey, N., Strider, J., Nolan, W. C., Yan, S. X., & Galvin, J. E. (2008). Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathologica, 115(4), 479–489. doi:10.1007/s00401-007-0332-4.
90. Patil, R. R., Gholave, A. R., Jadhav, J. P., Yadav, S. R., & Bapat, V. A. (2015). Mucuna sanjappae Aitawade et Yadav: A new species of Mucuna with promising yield of anti-Parkinson’s drug l-DOPA. Genetic Resources and Crop Evolution, 62(1), 155–162. doi:10.1007/s10722-014-0164-8.
91. Philippu, A., Matthaei, H., & Lentzen, H. (1975). Uptake of dopamine into fractions of pig caudate nucleus homogenates. Naunyn-Schmiedeberg’s Archives of Pharmacology, 287(2), 181–190.
92. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the α-synuclein gene identified in families with parkinson’s disease. Science, 276(5321), 2045–2047. doi:10.1126/science.276.5321.2045.
93. Rajeswari, A., & Sabesan, M. (2008). Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson’s disease induced by MPTP neurodegeneration in mice. Inflammopharmacology, 16(2), 96–99. doi:10.1007/s10787-007-1614-0.
94. Rojas, P., Montes, P., Rojas, C., Serrano-García, N., & Rojas-Castañeda, J. C. (2012). Effect of a phytopharmaceutical medicine, Ginko biloba extract 761, in an animal model of Parkinson’s disease: Therapeutic perspectives. Nutrition, 28(11–12), 1081–1088. doi:10.1016/j.nut.2012.03.007.
95. Safar, M. M., Abdallah, D. M., Arafa, N. M., & Abdel-Aziz, M. T. (2010). Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats. Brain Research, 1334, 58–64. doi:10.1016/j.brainres.2010.03.076.
96. Shi, C., Zhao, L., Zhu, B., Li, Q., Yew, D. T., Yao, Z., et al. (2009). Dosage effects of EGb761 on hydrogen peroxide-induced cell death in SH-SY5Y cells. Chemico-Biological Interactions, 180(3), 389–397. doi:10.1016/j.cbi.2009.04.008.
97. Shieh, D. E., Liu, L. T., & Lin, C. C. (2000). Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Research, 20(5A), 2861–2865.
98. Shults, C. W. (2005). Therapeutic role of coenzyme Q(10) in Parkinson’s disease. Pharmacology & Therapeutics, 107(1), 120–130. doi:10.1016/j.pharmthera.2005.02.002.
99. Shults, C. W., Oakes, D., Kieburtz, K., Beal, M. F., Haas, R., Plumb, S., et al. (2002). Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Archives of Neurology, 59(10), 1541–1550.
100. Siddique, Y. H., Ara, G., Jyoti, S., & Afzal, M. (2012). The dietary supplementation of nordihydroguaiaretic acid (NDGA) delayed the loss of climbing ability in Drosophila model of Parkinson’s disease. Journal of Dietary Supplements, 9(1), 1–8. doi:10.3109/19390211.2011.630716.
101. Siddique, Y. H., Mujtaba, S. F., Jyoti, S., & Naz, F. (2013). GC–MS analysis of Eucalyptus citriodora leaf extract and its role on the dietary supplementation in transgenic Drosophila model of Parkinson’s disease. Food and Chemical Toxicology, 55, 29–35. doi:10.1016/j.fct.2012.12.028.
102. Siddique, Y. H., Faisal, M., Naz, F., Jyoti, S., & Rahul, (2014). Role of Ocimum sanctum leaf extract on dietary supplementation in the transgenic Drosophila model of Parkinson’s disease. Chinese Journal of Natural, 12(10), 777–781. doi:10.1016/s1875-5364(14)60118-7.
103. Sikander, A., & Ikram ul, H. (2006). Innovative effect of illite on improved microbiological conversion of l-tyrosine to 3,4 dihydroxy phenyl l-alanine (l-DOPA) by Aspergillus oryzae ME2 under acidic reaction conditions. Current Microbiology, 53(5), 351–357. doi:10.1007/s00284-005-0220-x.
104. Singh, K., Singh, S., Singhal, N. K., Sharma, A., Parmar, D., & Singh, M. P. (2010). Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism. Chemico-Biological Interactions, 185(2), 81–93. doi:10.1016/j.cbi.2010.03.015.
105. Spasic, M. R., Callaerts, P., & Norga, K. K. (2009). AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. Neuroscientist, 15(4), 309–316. doi:10.1177/1073858408327805.
106. Spencer, J. P., Jenner, A., Aruoma, O. I., Evans, P. J., Kaur, H., Dexter, D. T., et al. (1994). Intense oxidative DNA damage promoted by l-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Letters, 353(3), 246–250.
107. Su, B. N., Cuendet, M., Hawthorne, M. E., Kardono, L. B., Riswan, S., Fong, H. H., et al. (2002). Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity. Journal of Natural Products, 65(2), 163–169.
108. Surwase, S. N., Patil, S. A., Jadhav, S. B., & Jadhav, J. P. (2012). Optimization of l-DOPA production by Brevundimonas sp. SGJ using response surface methodology. Microbial Biotechnology, 5(6), 731–737. doi:10.1111/j.1751-7915.2012.00363.x.
109. Tan, L. C., Koh, W. P., Yuan, J. M., Wang, R., Au, W. L., Tan, J. H., et al. (2008). Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. American Journal of Epidemiology, 167(5), 553–560. doi:10.1093/aje/kwm338.
110. Tharakan, B., Dhanasekaran, M., Mize-Berge, J., & Manyam, B. V. (2007). Anti-parkinson botanical Mucuna pruriens prevents levodopa induced plasmid and genomic DNA damage. Phytotherapy Research, 21(12), 1124–1126. doi:10.1002/ptr.2219.
111. Toyama, E. Q., Herzig, S., Courchet, J., Lewis, T. L, Jr, Loson, O. C., Hellberg, K., et al. (2016). Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science, 351(6270), 275–281. doi:10.1126/science.aab4138.
112. Twig, G., Elorza, A., Molina, A. J., Mohamed, H., Wikstrom, J. D., Walzer, G., et al. (2008). Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO Journal, 27(2), 433–446. doi:10.1038/sj.emboj.7601963.
113. Vaidya, A. B., Rajagopalan, T. G., Mankodi, N. A., Antarkar, D. S., Tathed, P. S., Purohit, A. V., et al. (1978). Treatment of Parkinson’s disease with the cowhage plant-Mucuna pruriens Bak. Neurology India, 26(4), 171–176.
114. van Leyen, K., Kim, H. Y., Lee, S. R., Jin, G., Arai, K., & Lo, E. H. (2006). Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke, 37(12), 3014–3018. doi:10.1161/01.STR.0000249004.25444.a5.
115. Wahlqvist, M. L., Lee, M. S., Hsu, C. C., Chuang, S. Y., Lee, J. T., & Tsai, H. N. (2012). Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism & Related Disorders. doi:10.1016/j.parkreldis.2012.03.010.
116. Wang, J. Y., Wu, J. N., Cherng, T. L., Hoffer, B. J., Chen, H. H., Borlongan, C. V., et al. (2001). Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Research, 904(1), 67–75.
117. Wang, J., Du, X. X., Jiang, H., & Xie, J. X. (2009a). Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells. Biochemical Pharmacology, 78(2), 178–183. doi:10.1016/j.bcp.2009.03.031.
118. Wang, J., Xu, H. M., Yang, H. D., Du, X. X., Jiang, H., & Xie, J. X. (2009b). Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins. Neurochemistry International, 54(1), 43–48. doi:10.1016/j.neuint.2008.10.003.
119. Wang, M. S., Boddapati, S., Emadi, S., & Sierks, M. R. (2010). Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson’s disease cell model. BMC Neuroscience, 11, 57. doi:10.1186/1471-2202-11-57.
120. Waxman, E. A., Emmer, K. L., & Giasson, B. I. (2010). Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation. Biochemical and Biophysical Research Communications, 391(3), 1415–1420. doi:10.1016/j.bbrc.2009.12.079.
121. Whitworth, A. J., Theodore, D. A., Greene, J. C., Benes, H., Wes, P. D., & Pallanck, L. J. (2005). Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson’s disease. [Comparative StudyResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov’tResearch Support, U.S. Gov’t, P.H.S.]. Proceedings of the National Academy of Sciences of the United States of America, 102(22), 8024–8029. doi:10.1073/pnas.0501078102.
122. Wu, Y., Li, X., Zhu, J. X., Xie, W., Le, W., Fan, Z., et al. (2011). Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson’s disease. Neurosignals, 19(3), 163–174. doi:10.1159/000328516000328516.
123. Xu, L., Chen, W. F., & Wong, M. S. (2009). Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson’s disease through the IGF-I receptor signalling pathway. British Journal of Pharmacology, 158(3), 738–748. doi:10.1111/j.1476-5381.2009.00361.x.
124. Xu, Y., Liu, C., Chen, S., Ye, Y., Guo, M., Ren, Q., et al. (2014). Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson’s disease. Cellular Signalling, 26(8), 1680–1689. doi:10.1016/j.cellsig.2014.04.009S0898-6568(14)00144-2.
125. Xu, Q., Kanthasamy, A., & Reddy, M. (2015). (−)-Epigallocatechin-3-gallate protects against TNF alpha and hydrogen peroxide induced apoptosis in a cell culture model of Parkinson’s disease. The FASEB Journal, 29(1 Suppl.), 922.9. http://www.fasebj.org/content/29/1_Supplement/922.9.short.
126. Yang, S.-F., Wu, Q., Sun, A., Huang, X., & Shi, J. (2001). Protective effect and mechanism of Ginkgo biloba leaf extracts for Parkinson disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Acta Pharmacologica Sinica, 22(12), 1089–1093.
127. Yang, S., Zhang, D., Yang, Z., Hu, X., Qian, S., Liu, J., et al. (2008). Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture. Neurochemical Research, 33(10), 2044–2053. doi:10.1007/s11064-008-9675-z.
128. Yeh, Y. C., Liu, T. J., Wang, L. C., Lee, H. W., Ting, C. T., Lee, W. L., et al. (2009). A standardized extract of Ginkgo biloba suppresses doxorubicin-induced oxidative stress and p53-mediated mitochondrial apoptosis in rat testes. British Journal of Pharmacology, 156(1), 48–61. doi:10.1111/j.1476-5381.2008.00042.x.
129. Yokoyama, H., Kuroiwa, H., Tsukada, T., Uchida, H., Kato, H., & Araki, T. (2010). Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Journal of Neuroscience Research, 88(7), 1522–1536. doi:10.1002/jnr.22310.
130. Yu, S., Zheng, W., Xin, N., Chi, Z. H., Wang, N. Q., Nie, Y. X., et al. (2010). Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Research, 13(1), 55–64. doi:10.1089/rej.2009.0908.
131. Zbarsky, V., Datla, K. P., Parkar, S., Rai, D. K., Aruoma, O. I., & Dexter, D. T. (2005). Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease. Free Radical Research, 39(10), 1119–1125. doi:10.1080/10715760500233113.
132. Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004). Iron, brain ageing and neurodegenerative disorders. Nature Reviews Neuroscience, 5(11), 863–873. doi:10.1038/nrn1537.
133. Zhang, S. M., Hernan, M. A., Chen, H., Spiegelman, D., Willett, W. C., & Ascherio, A. (2002). Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology, 59(8), 1161–1169.
134. Zhang, F., Shi, J. S., Zhou, H., Wilson, B., Hong, J. S., & Gao, H. M. (2010). Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Molecular Pharmacology, 78(3), 466–477. doi:10.1124/mol.110.064535.